after the destruction of her pancreatic tissue by the virus. To test this hypothesis, pregnant mice were given a dietary supplement (casein hydrolysate) from the beginning of pregnancy or from two days after administration of the virus (Lansdown et al. 1975 ). The fetuses from these animals at 18 days' gestation did not differ significantly in weight from non-infected controls, while those given virus but no supplement were significantly lower in weight. In addition the fetuses from infected animals not given a dietary supplement were found to have a low ratio of albumin/a1-fetoprotein which had previously been shown to be associated with retarded fetal development.
It is apparent from these investigations into maternal infections during pregnancy that fetal development sometimes may be severely impaired without microorganisms necessarily in-fecting the fetus. Furthermore, although this experimental work has been carried out with two different viruses, producing very different pathological changes in experimental animals, it seems possible that other infections, clinical and subclinical, in man and domestic animals may also impair maternal health at critical times during the developmental processes, bringing about impaired fetal development in the form of reduced fertility and intrauterine growth retardation. Anwsthesia of animals on experiment presents problems over and above those facing the clinician. The criteria of good analgesia, of loss of reflex activity and of muscle relaxation must all be satisfied where full surgical anaesthesia is rerequired but in addition the serious scientist should consider the interaction between the pharmacological agents used, the condition of the animal itself, and the experimental protocol. Invariably, minimal metabolic and physiological disturbance is demanded. Unfortunately the limited knowledge of the normal cardiovascular behaviour, tissue fluid distribution and enzyme pathways in so many of the laboratory species in response to different agents often makes it impossible to predict the exact outcome of a given permutation. The difficulties are compounded by wide species differences, as well as age, strain; sex and even biological rhythmic differences within species.
A few simple rules are common to all. First homeostasis has to be maintained. Heat loss can be catastrophic, particularly in small animals such as mice, marmosets and squirrel monkeys, which present a high surface area relative to their body mass; fluid loss even in the absence of hemorrhage is enormous relative to total body fluid; poor ventilation due to partially blocked airways is a common cause of failure. The remedies are selfevident but are usually ignored. The anmsthetist should pay close attention to the immediate environment of the subject, providing a source of heat, fluid therapy whenever practicable, and a constant supply of oxygen-enriched gas delivered by endotracheal tube or tracheotomy, preferably by positive pressure ventilation. The health of the animal, particularly with reference to respiratory function, should always be considered and animals obtained from barrier maintained colonies or hysterectomy derived herds used wherever possible.
Of the inhalation agents nitrous oxide (50:50 with oxygen) with methoxyflurane in low concentrations are by far the safest agents for all species, particularly small and immature animals. A choice of injectable agents is now available, of which methoxhexitone (barbiturates), ketamine (dissociative anesthetics), CT1341 (anesthetic steroids), diazepam and acetylpromazine (ataractics), and a fentanyl/fluanisone combination (neuroleptanalgesic) are the most valuable. Judicious combinations of these agents can contribute to total efficiency, yet maintain the animal in a light state of central nervous system narcosis. Toxicity of the clinical inhalational anesthetics, now extensively investigated in animals, is often related to their biotransformation products, some of which are poisonous.
One of the most dramatic examples of postanaesthetic toxicity occurs with fluroxene. This is a well-established agent for clinical use in humans, which has proved to be lethal in beagles, mongrel dogs, cats and rabbits (Johnston et al. 1973) . A similar lethality in mice and rats can be modified by stimulation or suppression of drug-metabolizing enzymes (Cascorbi & Singh-Amaranath 1973 , Harrison & Smith 1973 . Recently, female mice have been found to be less susceptible (Gorsky et al. 1975) . Trifluoroethanol is probably the principal toxic fluroxene metabolite (Johnston & Stevens 1972 ) but qualitative and quantitative differences between species complicate the extrapolation of these findings to primates and man (Munson et al. 1974 , Wardell 1973 .
Biotransformation of halothane and fluroxene in miniature swine , Sawyer et al. 1972 ) and enflurane and methoxyflurane in rats appears to be relatively morq efficient at low doses of anaesthetics. Many agents have now been investigated at subaneesthetic concentrations (Halsey et al. 1971) .
Chronic exposure exaggerates the production and toxicity of metabolites. Mice, rats, guineapigs and rabbits exposed to very low doses of halothane continuously for five weeks develop hepatic lesionsrabbits and guinea-pigs being the most susceptible . Similar experiments have now been done with low doses of fluroxene (Stevens & Gibbons 1973) . Current studies at the Clinical Research Centre, with Professor G G Harrison from Cape Town and Dr W D B Pope from Winnipeg, have demonstrated that the toxicity of chronic exposure of rats to 10-50 parts/106 of fluroxene is increased by pretreatment with phenobarbitone.
These and other animal investigations in anwsthesia research are relevant to the continuing clinical problems of both post-aneesthetic toxicity in patients and the health hazards of anesthetic pollution in the operating-room.
